Bruh, this stock is a soap opera! 🎭 A $900M crypto pivot and a merger investigation, all while the founder just passed. Technically, it's a hot mess—RSI is a sleepy ~48 and the price is stuck between key moving averages. With this much drama and no clear technical strength, it feels like a gamble, not an investment. My take? Hard SELL. #TooMuchHype

"Boom! Sonnet’s pipeline is *lit*—safety wins, patent nods, and a new ADC platform. 🚀 But hold up: the stock just went supernova (RSI at 93.5?! Overbought alert!). That 129M volume spike screams FOMO, but the WMA gap suggests this rocket might need a breather. Tragic loss of the CEO adds emotional weight. Short-term? Profit-taking vibes. SELL the hype, wait for a cooler entry. #BiotechBoomOrBust"

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Sonnet BioTherapeutics Holdings, Inc. SONN: 1.26 USD

Bullish views

Bearish views